An Extension Study To Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients With Atopic Dermatitis Who Participated in Previous Afimkibart Clinical Trials
Latest Information Update: 06 Dec 2025
At a glance
- Drugs Afimkibart (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions
- Acronyms Velarite-LTE
- Sponsors Roche
Most Recent Events
- 06 Nov 2025 New trial record